U.S. markets close in 5 hours 52 minutes

Dunxin Financial Holdings Limited (DXF)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
1.3800-0.0200 (-1.43%)
As of 10:02AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.4000
Open1.3800
Bid1.3800 x 1000
Ask1.3800 x 1000
Day's Range1.3699 - 1.4000
52 Week Range0.3700 - 2.8800
Volume27,897
Avg. Volume1,614,795
Market Cap28.807M
Beta (5Y Monthly)1.54
PE Ratio (TTM)8.47
EPS (TTM)0.1630
Earnings DateMay 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.07
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
15% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Dunxin Financial Holdings Limited Announced the signing of Intentional Cooperation Agreement with Baite Biological Group Co., Ltd.
    PR Newswire

    Dunxin Financial Holdings Limited Announced the signing of Intentional Cooperation Agreement with Baite Biological Group Co., Ltd.

    Dunxin Financial Holdings Limited ("Dunxin" or the "Company" NYSE American: DXF), a licensed microfinance lender serving individuals and small and medium enterprises (SMEs) in Hubei Province, China, today announced that the Company signed an Intentional Cooperation Agreement with Baite Biological Group Co., Ltd. The Company and Baite Biological Group plan to carry out cooperation in market expansion and production research and development in three aspects: (1) In Vitro Diagnostic industry, (2) hospital intelligent laboratory, (3) production and manufacturing of high-end medical devices.